E I D-Parry (India) Ltd
NSE:EIDPARRY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (4.3), the stock would be worth ₹886.87 (4% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.1 | ₹853.75 |
0%
|
| 3-Year Average | 4.3 | ₹886.87 |
+4%
|
| 5-Year Average | 3.9 | ₹818.79 |
-4%
|
| Industry Average | 19.1 | ₹3 976.72 |
+366%
|
| Country Average | 23.3 | ₹4 843.56 |
+467%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
₹112.3B
|
/ |
Jan 2026
₹26.9B
|
= |
|
|
₹112.3B
|
/ |
Mar 2026
₹34.5B
|
= |
|
|
₹112.3B
|
/ |
Mar 2027
₹40.5B
|
= |
|
|
₹112.3B
|
/ |
Mar 2028
₹50.4B
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
E I D-Parry (India) Ltd
NSE:EIDPARRY
|
151.3B INR | 4.1 | 12.8 | |
| US |
|
Corteva Inc
NYSE:CTVA
|
54B USD | 19.3 | 49.2 | |
| CA |
|
Nutrien Ltd
TSX:NTR
|
46.8B CAD | 12.4 | 15.1 | |
| CN |
|
Qinghai Salt Lake Industry Co Ltd
SZSE:000792
|
198.5B CNY | 25.1 | 23.4 | |
| CL |
|
Sociedad Quimica y Minera de Chile SA
NYSE:SQM
|
25.3B USD | 27.2 | 42.6 | |
| CN |
|
Zangge Mining Co Ltd
SZSE:000408
|
135.9B CNY | 80.7 | 29 | |
| US |
|
CF Industries Holdings Inc
NYSE:CF
|
17.8B USD | 8.5 | 12.8 | |
| SA |
|
SABIC Agri-Nutrients Company SJSC
SAU:2020
|
53.8B SAR | 10 | 12.4 | |
| NO |
|
Yara International ASA
OSE:YAR
|
133.3B NOK | 9.9 | 10.3 | |
| RU |
|
PhosAgro PAO
MOEX:PHOR
|
914.9B RUB | 6 | 7.9 | |
| CN |
|
Shandong Hualu-Hengsheng Chemical Co Ltd
SSE:600426
|
74.4B CNY | 18 | 22.4 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 15.7 |
| Median | 23.3 |
| 70th Percentile | 34.7 |
| Max | 48 145.1 |
Other Multiples
E I D-Parry (India) Ltd
Glance View
In the bustling world of agribusiness, E I D-Parry (India) Ltd. emerges as a formidable player deeply rooted in the agricultural heartland of India. Founded in 1788, the company has evolved over two centuries to become a significant name in the sugar and nutraceutical arenas. At the core of its operations lies the sugar production segment, which remains a substantial contributor to its revenue stream. Encompassing sugarcane cultivation, processing, and refined sugar production, E I D-Parry leverages extensive expertise and technological advancements to maintain efficiency. By investing in integrated factories, which include state-of-the-art distilleries and cogeneration plants, the company optimizes its byproducts, efficiently producing ethanol and generating power for the grid. This approach not only maximizes profit margins but also underscores a commitment to sustainability. Beyond the traditional sugar business, E I D-Parry takes strides into the growing nutraceutical market, sensing the opportunity to capitalize on the increasing global wellness trend. Through its subsidiary, Parry Nutraceuticals, the company delves into the extraction and commercialization of high-value health supplements, such as spirulina and microalgae. This diversification is not only a hedge against the volatile sugar market but also a step towards leveraging its expertise in fermentation technology. By strategically expanding its portfolio and tapping into value-added products, E I D-Parry crafts a multifaceted business model that stays resilient amid cyclical agricultural dynamics, positioning itself as a forward-thinking entity in both local and international markets.